Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PYPD 
PolyPid (PYPD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PYPD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.97% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.26M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 4 | Beta 1.5 | 52 Weeks Range 2.30 - 3.93 | Updated Date 10/17/2025 |
52 Weeks Range 2.30 - 3.93 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.2% | Return on Equity (TTM) -312.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34219315 | Price to Sales(TTM) - |
Enterprise Value 34219315 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.36 | Shares Outstanding 15897201 | Shares Floating 8763181 |
Shares Outstanding 15897201 | Shares Floating 8763181 | ||
Percent Insiders 16.7 | Percent Institutions 41.2 |
Upturn AI SWOT
PolyPid
Company Overview
History and Background
PolyPid, founded in 2008, is a biopharmaceutical company focused on developing and commercializing locally administered, controlled-release therapeutics using its proprietary PLEX technology. It aims to improve surgical outcomes by reducing infection risk.
Core Business Areas
- Surgical Site Infections (SSI) Prevention: This is the core focus, with products designed to prevent infections following surgical procedures.
- Controlled-Release Drug Delivery: Developing platforms for localized and prolonged drug release.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and medical device industries. The company has a standard organizational structure with departments focusing on R&D, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- D-PLEX100: D-PLEX100 is PolyPid's lead product candidate, designed to prevent surgical site infections. Competitors include traditional systemic antibiotics and other local antibiotic delivery systems. Market share is still evolving as it gains approval in various regions. The FDA approved D-PLEX100 on September 25, 2023.
Market Dynamics
Industry Overview
The surgical site infection prevention market is a growing area within healthcare, driven by increasing surgical procedures and the rising cost of treating infections.
Positioning
PolyPid aims to be a key player in the SSI prevention market by offering a localized, controlled-release antibiotic solution.
Total Addressable Market (TAM)
The global surgical site infection (SSI) treatment market was valued at $5.7 billion in 2023. PolyPid is targeting a portion of this TAM with D-PLEX100 and future products.
Upturn SWOT Analysis
Strengths
- Proprietary PLEX technology
- Targeted drug delivery
- Focus on SSI prevention
- FDA Approved D-PLEX100
Weaknesses
- Reliance on a single lead product
- Need for further clinical validation
- Limited commercialization experience
- High R&D expenses
Opportunities
- Expanding product applications
- Partnerships and collaborations
- Market expansion to new regions
- Increased awareness of SSI prevention
Threats
- Competition from established players
- Regulatory hurdles
- Pricing pressures
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- MTOR
- Bactiguard
- TherapeuticsMD (TXMD)
Competitive Landscape
PolyPid's advantage lies in its PLEX technology for controlled drug release. Disadvantages include limited resources compared to larger, established companies.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been defined by progress in clinical trials and regulatory approvals.
Future Projections: Future growth is projected to be driven by the commercial success of D-PLEX100 and the development of additional products.
Recent Initiatives: Recent initiatives include seeking regulatory approvals for D-PLEX100 and establishing commercial partnerships.
Summary
PolyPid is a growing biopharmaceutical company with FDA approved D-PLEX100 and with novel controlled-release technology for surgical site infection prevention. This offers a unique value proposition in a growing market. The company still has financial and scaling challenges as a pre-revenue organization; however, it has great potential to prevent infections after surgery. PolyPid needs to execute its commercialization strategy effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, press releases, analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data may be estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PolyPid
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-06-26 | CEO & Director Ms. Dikla Czaczkes Akselbrad | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.polypid.com |
Full time employees 57 | Website https://www.polypid.com | ||
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.